Long-Term Benefit of Rituximab in Systemic Sclerosis A small cohort trial of rituximab (RTX) in 29 systemic sclerosis
Tweet Content
Long-Term Benefit of Rituximab in Systemic Sclerosis
A small cohort trial of rituximab (RTX) in 29 systemic sclerosis patients showed significantly improved skin sclerosis and lung function after a follow-up of 96 weeks.
https://t.co/f68wc6lQGH https://t.co/G4PKPnJ0LJ
Links
Show on Archive Page
On
Display in Search Results
On
PDQ
Off